The strategic consequences of the recast of the EMCDDA founding regulation on the agency's activities were among the points for discussion at the latest Management Board meeting held in Lisbon from 4–6 July.
The new regulation, which entered into force on 16 January 2007, broadens the scope of the agency's tasks, granting it a more active role in monitoring new patterns of drug use and related trends. Specifically it allows the agency to collect, register and analyse information on 'emerging trends in polydrug use', including the combined use of licit and illicit psychoactive substances. It also states that the EMCDDA should provide information on best practice in the EU Member States and may be called on to transfer its know-how to certain non-EU countries, such as official candidates for EU accession.
Areas with potential for development were discussed, although the speed at which these will be taken forward will depend on priority setting and resource availability. The Management Board revised its rules of procedure in the light of the recast and adopted procedures for the selection and appointment of the members of a new Scientific Committee. The Board also took note of a new EMCDDA communication strategy.
Drugnet Europe is the EMCDDA's newsletter launched in September 1996. The newsletter provides regular and succint information on the Centre's projects and activities to a broad readership.